Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification.

IF 3.9 3区医学 Q1 PATHOLOGY

Expert Review of Molecular Diagnostics Pub Date : 2023-07-01 Epub Date: 2023-12-15 DOI:10.1080/14737159.2023.2277366

Matteo Ferro, Bernardo Rocco, Martina Maggi, Giuseppe Lucarelli, Ugo Giovanni Falagario, Francesco Del Giudice, Felice Crocetto, Biagio Barone, Evelina La Civita, Francesco Lasorsa, Antonio Brescia, Michele Catellani, Gian Maria Busetto, Octavian Sabin Tataru, Daniela Terracciano

{"title":"Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification.","authors":"Matteo Ferro, Bernardo Rocco, Martina Maggi, Giuseppe Lucarelli, Ugo Giovanni Falagario, Francesco Del Giudice, Felice Crocetto, Biagio Barone, Evelina La Civita, Francesco Lasorsa, Antonio Brescia, Michele Catellani, Gian Maria Busetto, Octavian Sabin Tataru, Daniela Terracciano","doi":"10.1080/14737159.2023.2277366","DOIUrl":null,"url":null,"abstract":"Introduction: New potential biomarkers to pre-intervention identification of a clinically significant prostate cancer (csPCa) will prevent overdiagnosis and overtreatment and limit quality of life impairment of PCa patients.Areas covered: We have developed a comprehensive review focusing our research on the increasing knowledge of the role of SelectMDX® in csPCa detection. Areas identified as clinically relevant are the ability of SelectMDX® to predict csPCa in active surveillance setting, its predictive ability when combined with multiparametric MRI and the role of SelectMDX® in the landscape of urinary biomarkers.Expert opinion: Several PCa biomarkers have been developed either alone or in combination with clinical variables to improve csPCa detection. SelectMDX® score includes genomic markers, age, PSA, prostate volume, and digital rectal examination. Several studies have shown consistency in the ability to improve detection of csPCa, avoidance of unnecessary prostate biopsies, helpful in decision-making for clinical benefit of PCa patients with future well designed, and impactful studies.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Molecular Diagnostics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737159.2023.2277366","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: New potential biomarkers to pre-intervention identification of a clinically significant prostate cancer (csPCa) will prevent overdiagnosis and overtreatment and limit quality of life impairment of PCa patients.

Areas covered: We have developed a comprehensive review focusing our research on the increasing knowledge of the role of SelectMDX® in csPCa detection. Areas identified as clinically relevant are the ability of SelectMDX® to predict csPCa in active surveillance setting, its predictive ability when combined with multiparametric MRI and the role of SelectMDX® in the landscape of urinary biomarkers.

Expert opinion: Several PCa biomarkers have been developed either alone or in combination with clinical variables to improve csPCa detection. SelectMDX® score includes genomic markers, age, PSA, prostate volume, and digital rectal examination. Several studies have shown consistency in the ability to improve detection of csPCa, avoidance of unnecessary prostate biopsies, helpful in decision-making for clinical benefit of PCa patients with future well designed, and impactful studies.

查看原文本刊更多论文

血液生物标志物之外：SelectMDX在临床意义重大的前列腺癌症识别中的作用。

引言：新的潜在生物标志物用于临床意义的癌症（csPCa）的干预前识别，将防止过度诊断和过度治疗，并限制PCa患者的生活质量损害。涵盖的领域：我们制定了一份全面的综述，重点研究SelectMDX®在csPCa检测中的作用。被确定为临床相关的领域包括SelectMDX®在主动监测环境中预测csPCa的能力，其与多参数MRI相结合的预测能力，以及SelectMDX在尿液生物标志物领域中的作用。专家意见：已经单独或结合临床变量开发了几种前列腺癌生物标志物，以提高前列腺癌的检测。SelectMDX®评分包括基因组标记、年龄、PSA、前列腺体积和直肠指检。几项研究表明，在提高csPCa检测能力、避免不必要的前列腺活检、有助于PCa患者临床利益的决策方面，未来的研究设计良好，效果显著。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Molecular Diagnostics 医学-病理学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Expert Review of Molecular Diagnostics (ISSN 1473-7159) publishes expert reviews of the latest advancements in the field of molecular diagnostics including the detection and monitoring of the molecular causes of disease that are being translated into groundbreaking diagnostic and prognostic technologies to be used in the clinical diagnostic setting. Each issue of Expert Review of Molecular Diagnostics contains leading reviews on current and emerging topics relating to molecular diagnostics, subject to a rigorous peer review process; editorials discussing contentious issues in the field; diagnostic profiles featuring independent, expert evaluations of diagnostic tests; meeting reports of recent molecular diagnostics conferences and key paper evaluations featuring assessments of significant, recently published articles from specialists in molecular diagnostic therapy. Expert Review of Molecular Diagnostics provides the forum for reporting the critical advances being made in this ever-expanding field, as well as the major challenges ahead in their clinical implementation. The journal delivers this information in concise, at-a-glance article formats: invaluable to a time-constrained community.